Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating sintilimab with IBI305 versus sorafenib as first-line therapy for advanced hepatocellular carcinoma (PHASE 2/3). Status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IBI305 (bevacizumab biosimilar)
• Sintilimab (sintilimab)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: UNKNOWN